



Supplemental Figures



Supplementary Figure S1. Identification of SKP-SCs. **(A)** The SCs from SKP were spindle-shaped and arranged in parallel. Scale bar = 100 μ m. **(B)** SCs derived from SKP were positive for GFAP (green) and S-100 β (red), and the nucleus was labeled with DAPI (blue). Scale bar = 50 μ m (low magnification); scale bar = 20 μ m (high magnification). SCs, Schwann cells; SKP, skin-derived precursors.



Supplementary Figure S2. SKP-SC-EV biological activity verification. **(A)** MHC immunofluorescence staining of C2C12 myotubes. Myotubes after hypoxia were treated with different doses of SKP-SC-EVs. After 12 hours of hypoxia, we observed the effects of SKP-SC-EVs on

C2C12 myotubes. Scale bar = 20 μm . **(B)** Histogram indicating the change in myotube diameter in different-dose treatment groups. *** $p < 0.001$ and **** $p < 0.0001$ vs. control (Ctrl) group; #### $p < 0.0001$ vs. 0 group. EVs, extracellular vesicles. SCs, Schwann cells; SKP, skin-derived precursors.